John Armstrong

John Armstrong supports clients with research and analysis that spans a variety of healthcare sectors and stakeholders.

He applies his background in pharmaceutical policy and health systems research to a broad range of client projects.

Prior to joining Avalere, John held a variety of internship positions, including an internship with the National Conference of State Legislatures, where he tracked state policy changes in pharmaceutical cost and access and wrote briefs on value-based care and alternative payment models. Additionally, he has worked at the breast-cancer non-profit Komen Colorado doing policy advocacy and on the WHO Health Systems in Transition project at the Technical University of Berlin doing quantitative research on recent trends in different healthcare systems.

John has a BS in biopsychology from Tufts University and an MPH in health systems, management and policy from the Colorado School of Public Health.

Authored Content

The Patient Centered Outcomes Research Institute (PCORI) recently announced an open comment period for a new set of proposed national priorities to inform its research agenda. Avalere analysis finds that from March 2019 to September 2020, PCORI directed roughly $259 million to comparative effectiveness research (CER) awards with an increasing share of new projects focused on drugs.

On March 8–9, the Presidential Advisory Council on HIV/AIDS (PACHA) discussed avenues to achieving equitable access to HIV prevention products for at-risk populations as well as next steps in revising the National Strategic Plan to End the HIV Epidemic.

On May 13, Avalere experts discussed key issues and considerations for the healthcare industry as millions of Americans shift in and out of new sources of coverage due to COVID-19.

In a recent webinar, experts from Avalere and the National Patient Advocate Foundation discussed the value of shared decision-making (SDM) and preparing patients and families for navigating their care journeys.

On April 9, Avalere experts came together to discuss the impact of COVID-19 on the health insurance industry.